Clinical Trials Logo

Safety clinical trials

View clinical trials related to Safety.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03832517 Terminated - Safety Clinical Trials

Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

Start date: April 14, 2019
Phase: Phase 1
Study type: Interventional

A Phase 1 study of the safety, tolerability and pharmacokinetics of a new antibiotic (RC-01). In Part 1 cohorts of healthy adults will participate in a single dose escalation study of increasing intravenous doses of RC-01. In Part 2 cohorts of healthy adults will participate in a multiple dose escalation study of increasing intravenous doses of RC-01 given either twice daily or three times daily.

NCT ID: NCT03503968 Terminated - Safety Clinical Trials

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

Start date: March 27, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, non-randomized, open-label, Phase I/II clinical trial of MDG1011, an investigational medicinal product (IMP), consisting of patient-derived autologous T cells, persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific human leukocyte antigen (HLA)-A*02:01-restricted T cell receptor (TCR).

NCT ID: NCT03067363 Terminated - Safety Clinical Trials

First in Human Single Ascending Dose Study of MOR107

Start date: February 16, 2017
Phase: Phase 1
Study type: Interventional

This is the first in human study of MOR107. It is a 2 part, single centre, double-blind, randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects on a low sodium diet.

NCT ID: NCT02209506 Terminated - Pharmacokinetics Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants

Start date: July 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single and multiple oral dosing of MLN3126 in ascending doses in healthy non-Japanese and Japanese participants.

NCT ID: NCT02046590 Terminated - Anesthesia Clinical Trials

RCT of Efficacy and Safety of Sedation Compared to General Anesthesia for ERCP

Start date: February 2014
Phase: N/A
Study type: Interventional

There is a worldwide trend to minimally invasive interventions, which results in increasing numbers of interventions performed outside of the operating room. Currently, approximately 12 to 15% of total anaesthetic workload is non-operating room anaesthesia (NORA) and this anaesthetic activity is increasing. Many of these interventions need supplementary comfort measures to have relaxed patients and high success rates. Endoscopic retrograde cholangio-pancreatography (ERCP) is performed >50,000 times per year in the U.S.,and is a typical minimally invasive intervention that needs patient sedation. There is a controversy about the optimal comfort intervention in minimally invasive interventions and in particular in ERCP. Two different approaches to insure patients' comfort have been proposed: general anaesthesia with endotracheal intubation and mechanical ventilation or sedation with spontaneous ventilation. Well-performed studies on sedation versus general anaesthesia using a randomized controlled trial design with observer blinding will contribute to improve the decision-making for the optimal comfort measures in minimally invasive procedures. At our knowledge such a randomized controlled trial has not been reported before. The investigators hypothesize that deep sedation without tracheal intubation will achieve similar success rates for ERCP as general anaesthesia and will have similar rates of harmful postoperative effects. The primary aim of this trial is to demonstrate that the success rate of ERCP is not inferior in patients randomized to deep sedation without orotracheal intubation vs general anesthesia with orotracheal intubation. Secondary aims include a comparison between randomization groups of patient safety, patient and endoscopist satisfaction, duration of patient recovery and of anesthesia procedure.

NCT ID: NCT01929811 Terminated - Safety Clinical Trials

NeoMET Study in Neoadjuvant Treatment of Breast Cancer

NeoMET
Start date: October 2013
Phase: Phase 2
Study type: Interventional

To evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients. The aim is to evaluate whether metformin can increase the pCR rate combination with TEC regimen in neoadjuvant setting.